Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JDQ443 dose-escalation and dose-expansion study in KRAS G12C-mutant advanced solid tumors
NL-OMON54361Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of opnurasib, batoprotafib and tislelizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (7 arms), sponsored by Novartis. Primary endpoints: Best Overall Response, Overall Response Rate and 10 more. Started Jul 2021; status: recruiting.
02
Drugs
opnurasibbatoprotafibtislelizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON54361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54361.